Cytek Biosciences (CTKB) Depreciation and Depletion (2020 - 2026)

Cytek Biosciences has reported Depreciation and Depletion for 7 years, with the latest figure at $1.0 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation and Depletion rose 11.11% year-over-year to $1.0 million; the trailing twelve-month figure through Mar 2026 stood at $4.0 million (up 11.11% YoY), and the FY2025 full-year result was $3.9 million, up 11.43% from the prior year.
• Depreciation and Depletion for Q1 2026 stood at $1.0 million, roughly flat from $1.0 million in the prior quarter.
• The five-year high for Depreciation and Depletion was $1.0 million in Q2 2025, with the low at $300000.0 in Q1 2022.
• Historically, Depreciation and Depletion has averaged $752941.2 across 5 years, with a median of $900000.0 in 2023.
• Annual changes were most pronounced in 2023 — Depreciation and Depletion soared 125.0% — and 2024, when it changed 0.0%.
• Cytek Biosciences' Depreciation and Depletion stood at $500000.0 in 2022, then soared by 60.0% to $800000.0 in 2023, then increased by 12.5% to $900000.0 in 2024, then rose by 11.11% to $1.0 million in 2025, then changed by 0.0% to $1.0 million in 2026.
• The last three Depreciation and Depletion figures came in at $1.0 million (Q1 2026), $1.0 million (Q4 2025), and $1.0 million (Q3 2025), per Business Quant data.